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Abstract
Background: This study was initiated to investigate the difference in HER2 status between tumor tissue and
circulating tumor cells (CTCs), as well as the predictive value of CTC HER2 status for predicting the outcomes
of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer (MBC) patients.
Methods: HER2 expression on CTCs was detected using a CellSearch system within 7 days before a new line of
anti-HER2 therapy was begun. According to the criterion proposed in our previous report, patients were defined
as CTC HER2-positive or -negative. After close follow-up, the correlation between CTC HER2 status and the outcome
of the treatment was evaluated by statistical analysis.
Results: CTCs were detected in 57.4 % (58/101) of the patients. Notably, 62.1 % (36/58) of these patients had an
inconsistent HER2 status between their tissue and CTCs. The discordant rate may correlate with the time interval
between histological and CTC HER2 testing and is more likely to occur in the subgroup of patients with an interval
of > 1 year than in those with an interval < 1 year (70.7 % vs. 41.2 %, P = 0.043). For PFS, positive HER2 status on
CTCs was shown to be a valuable predictor, both in univariate (HR = 0.321, 95%CI, 0.156–0.62, P = 0.0011) and
multivariate (HR = 0.383, 95%CI, 0.166–0.831, P = 0.019) Cox regression analysis. Meanwhile, Kaplan-Meier survival
curves revealed that the median PFS of CTC HER2-positive patients was significantly longer than CTC HER2-negative
ones (8.5 vs. 3.5 months, P < 0.001).
Conclusions: HER2 status on CTCs was different from that of tumor tissues and predicted a different outcome of
the patients’ anti-HER2 therapy. This difference may be correlated with the time interval between tissue and CTC
HER2 testing, indicating the necessity of real-time HER2 analysis for histologically HER2-positive MBC patients.
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Background
Human epidermal growth factor receptor 2 (HER2), also
known as Erb-B2, is a well-recognized tumor marker that
plays significant roles in cancer cell survival and prolifera-
tion [1]. The over-expression of this 185 kDa transmem-
brane tyrosine kinase receptor or the amplification of this
gene located on human chromosome 17q21 results in what
is called the HER2-positive molecular subtype of breast
cancer that occurs in approximately 20 % of patients [2, 3]
and is associated with worse outcome. The introduction of
anti-HER2 therapy, such as trastuzumab, lapatinib, pertu-
zumab, and trastuzumab emtansine (T-DM1), has resulted
in dramatic improvements in outcome of primary and
metastatic disease [4–7].
Currently, the HER2 status of breast cancer patients is
mainly determined by immunohistochemistry (IHC) or
fluorescent in situ hybridization (FISH) on a section of
tumor tissue obtained by surgery or needle biopsy. A posi-
tive result was defined by circumferential membrane
staining that is complete, intense, and within > 10 % of
tumor cells via the IHC method and/or HER2 copy
number ≥ 6 signal/cell or a signal ratio of HER2 gene to
chromosome 17 ≥ 2.0 by the FISH method [8, 9]. How-
ever, previous studies demonstrated that not all HER2-
positive metastatic breast cancer (MBC) patients screened
by the above 2 methods benefit from anti-HER2 therapy.
The objective response rate (ORR) of single-agent trastu-
zumab and chemotherapy plus trastuzumab was, respec-
tively, 26 % [10] and 50 % [11]. The ORR for chemotherapy
plus lapatinib was no better at approximately 25 % [12].
Additionally, a cohort of patients with HER2-positive dis-
ease can develop disease recurrence or progression during
trastuzumab or other HER-2 targeted therapy raising ques-
tions regarding the resistance mechanisms and most appro-
priate diagnostic modalities for treatment selection.
One possible explanation of the limited efficacy and
resistance demonstrated in some patients is that the
assessment results of the HER2 status may be inaccurate
due to the inevitable system errors caused by tumor
heterogeneity, subjectivity in result interpretation, and
related factors [13]. In addition, considering that tumor
cells are constantly evolving or undergoing clonal selec-
tion, and the acquisition of tumor tissue is invasive and
difficult to perform dynamically, the detected HER2 status
may not necessarily reflect patients’ real-time phenotypes
and may therefore misinform the subsequent anti-HER2
therapy.
In contrast, circulating tumor cells (CTCs), the cancer
cells that detach from the tumor and circulate in the
peripheral blood as the cellular origin of metastasis, may
offer a promising alternative for real-time HER2 detec-
tion with the advantages of minimal invasiveness and
convenient accessibility [14–17]. Termed as a “liquid
biopsy”, the enumeration and characterization of CTCs
has demonstrated its clinical utility in prognosis and the
prediction of therapy outcome, monitoring disease pro-
gression, and evaluating treatment responses [18–20].
With regard to HER2 in breast cancer, many research
teams have made great efforts to compare the expression
difference between tumor tissue and CTCs, aiming to
correlate the real-time HER2 status of CTCs with patient’s
response to anti-HER2 therapy [14, 21]. Nevertheless, the
methods used in these studies were varied. More impor-
tantly, a widely accepted positive criterion has not yet
been discovered, which has greatly hampered the applica-
tion of CTC HER2 status in clinical practice.
The CellSearchTM system (Veridex LLC, USA) is the
only CTC assay that been approved by the Food and Drug
Administration (FDA) of USA and China [18, 19]. The
semi-automatic design of the machine, together with its
commercialized reagent kit, eliminates the influence of
man-made factors as much as possible and ensures the
accuracy, reliability, and reproducibility of this system
[22]. By staining the CTCs with a fluorescein isothiocyan-
ate (FITC)-labeled anti HER2 antibody, the HER2 expres-
sion of the enriched CTCs can be successfully assessed in
the fourth channel of the CellSearch™ system. Based on
this technology, Pestrin et al. claimed that a patient can be
defined as CTC HER2-positive when at least 50 % of the
CTCs exhibit HER2 immunofluorescence (IF) signals [23].
On the contrary, some researchers recognized that each
CTC’s HER2 intensity was not identical (scored as 0, 1+, 2
+, or 3+) and insisted that a patient can be categorized as
CTC HER2-positive if at least 1 CTC showed HER2 stain-
ing scored as 3+ [24, 25].
Though the clinical evidence for these 2 definitions
was lacking, they gave us the valuable indication that a
reasonable criterion for CTC HER2 positivity should
take both the HER2 intensity and the percentage of
CTCs with the corresponding intensity into conside-
ration. Accordingly, a criterion set at > 30 % of CTCs
over-expressing HER2 (3+) was proposed in our previ-
ous study and preliminarily verified for the first time ac-
cording to the clinical outcome of anti-HER2 therapy
[21]. To obtain more robust evidence, this prospective
and more rationally designed study was initiated, and it’s
primary and secondary endpoint was the progression-
free survival (PFS) and the clinical value of our CTC
HER2 positive criterion, respectively. Our results further
underscore the importance and urgency of real-time
HER2 testing through CTCs.
Methods
Study design
Histologically HER2-positive MBC patients (defined by
the pathologist as IHC 3+ and/or a FISH ratio of more
than 2.0) who were planned to receive a new line anti-
HER2 therapy plus chemotherapy were enrolled in the
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present study. Eligible patients were required to have mea-
surable or evaluable disease, with an Eastern Cooperative
Oncology Group (ECOG) performance status score of 0 to
3, and with definite pathology report that described their
ER/PR and HER2 status. Within 7 days before the initiation
of therapy, 10 ml of peripheral blood was collected and
delivered to the laboratory for CTC analysis. All treatment
decisions for the patients were made according to the
National Comprehensive Cancer Network (NCCN) clinical
practice guidelines (Breast Cancer V.2.2011) without know-
ing the patients’ CTC results. The efficacy of the therapy
was evaluated with computed tomography (CT) scans every
6-8 weeks until discontinuation or as clinically indicated.
Responses were defined and categorized according to
Response Evaluation Criteria in Solid Tumors (RECIST)
1.1. After close follow-up, the relationship between CTC
HER2 expression and the outcome of anti-HER2 therapy
were assessed by statistical analysis.
All patients signed an informed consent to participate
in the study, which was approved by the ethics and
scientific committees of the Affiliated Hospital of the
Academy of Military Medical Sciences.
CTC analysis
CTC analysis was performed with a CellSearch™ system
(Veridex LLC, USA) according to the manufacturer’s
instructions as described elsewhere [21]. Briefly, CTCs were
immunomagnetically enriched using anti-epithelial cell
adhesion molecule (EpCAM)-conjugated magnetic beads
and then automatically stained with fluorescently tagged
monoclonal antibodies (CD45-allophycocyanin for leuko-
cytes and cytokeratin 8-, 18-, 19-phycoerythrin for CTCs)
and nucleic acid dye 4′, 6-diamidino-2-phenylindole
(DAPI). Those events with positive cytokeratin (CK), posi-
tive DAPI, negative CD45 and the appropriate cellular
morphology were defined as CTCs. HER2 expression on
CTCs was assessed by staining the cells with a FITC-
labeled anti-HER2 antibody (Veridex LLC, USA). Accord-
ing to the criterion described in our previous research [21],
the intensity of HER2 expression on each CTC was given a
score of 0 (negative), 1+ (weak), 2+ (moderate or questio-
nable), or 3+ (strong), and those patients with > 30 % of
CTCs over-expressing HER2 (3+) were defined as CTC
HER2-positive.
Statistical analysis
For different clinical characteristics, Fisher’s exact test was
used to test whether there was a significant difference
between the CTC HER2-positive and-negative patients,
and between CTC = 0 and CTC ≥1 patients. The rates of
discordance for HER2 status in groups with different time
intervals between tissue and CTC HER2 testing were
compared by Chi-square test. PFS was defined as the time
elapsed from the initiation of new line therapy to the
documentation of disease progression (according to
RECIST) or, if no progression was observed during the
follow-up, to the last follow-up visit. Univariate and multi-
variate Cox regression analysis was used to determine the
hazard ratio (HR) for the prediction of PFS. Kaplan-Meier
survival curves of PFS were generated based on CTC
HER2 status and compared by log-rank test. All statistical
analyses were two-sided and carried out using SAS soft-
ware version 9.2 (SAS Institute Inc., USA); P values < 0.05
were considered statistically significant.
Results
Patient characteristics and CTC detection
From September 2010 to November 2013, 101 histologi-
cally HER2-positive MBC patients with a median age of
48 years (range: 25 to 68) were enrolled in the present
study. Those patients were divided into CTC positive and
negative group, and their characteristics were shown in
Additional file 1: Table S1. CTCs were detected in 57.4 %
(58/101) of patients, with a mean value of 23, ranging
from 1 to 323. According to our positive criterion, the 58
patients were divided into CTC HER2-positive and-
negative groups. The patient characteristics of the 2
groups are listed in Table 1 and indicate that negative
CTC HER2 status may easily be found in patients consid-
ered to be ER-and/or PR-positive (P = 0.014). In addition,
no significant differences were found between the 2
groups in terms of age, metastatic number, metastatic
sites, disease-free survival (DFS), or systemic therapy line
and treatment option.
HER2 status on CTCs
According to the criterion described previously, HER2
expression intensity on each CTC was given a score of 0,
1+, 2+, or 3+. Representative images are shown in Fig. 1.
The percentages of CTCs at a given HER2 intensity score
(0, 1+, 2+, or 3+) as well as the treatment plans for each
patient are presented in Additional file 2: Table S2. Not-
ably, with the positive criterion defined as > 30 % of CTCs
with an HER2 positivity score of 3+, only 37.9 % (22/58)
of patients have a consistent HER2 status between their
tested tissue and CTCs. The remaining 62.1 % (36/58) of
histologically HER2-positive patients were actually CTC
HER2-negative. In the ER-and/or PR-positive subgroup
(Luminal type), the discordant rate between tissue and
CTCs reached 75.8 % (25/33). In addition, with regard to
the time interval between tissue and CTC HER2 testing,
the discordant rate in the subgroup of patients with an
interval > 1 year was significantly higher than that of the
subgroup of patients with an interval < 1 year (70.7 % vs.
41.2 %, P = 0.043). Similar results were also found for time
intervals of 2 and 3 years, but no significant difference was
found (data not shown).
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Cox regression analysis for PFS
The results of Cox regression analysis for PFS in patients
with CTC detection was shown in Table 2, which revealed
that positive HER2 status on CTCs was a valuable pre-
dictor for the patients’ PFS, both in univariate (HR =
0.321, 95 % CI, 0.156–0.62, P = 0.0011) and multivariate
(HR = 0.383, 95 % CI, 0.166–0.831, P = 0.019) analysis.
Among other characteristics, only ER and/or PR was
found to significantly correlate with patient’s PFS in uni-
variate analysis (HR = 1.854, 95 % CI, 1.015–3.454, P =
0.0467), but the significance disappeared in multivariate
analysis (HR = 1.977, 95 % CI, 0.928–4.39, P = 0.0841).
Considering that CTC HER2-negative patients may get
less benefit from anti-HER2 therapy, the correlation
between hormone receptor status and PFS may also
reflect the predictive value of CTC HER2 because 75.8 %
of ER- and/or PR-positive patients in our study were CTC
HER2-negative (Table 1). In addition, for all enrolled pa-
tients, CTC-and CTC+ groups were considered as a vari-
able and compared in univariate Cox regression analysis
for PFS, and the results revealed that CTC number not
correlated with patients’ PFS, not matter with cut-off of 1
(HR = 1.323, 95 % CI: 0.793–2.137, P = 0.2661) or 5 (HR =
1.329, 95 % CI: 0.849–2.102, P = 0.2168).
Kaplan-Meier survival curves of PFS according to CTC
count and CTC HER2 Status
Based on CTC number, the enrolled 101 patients were
divided into CTC =0 and CTC ≥ 1 groups, but the former
one didn’t show superior benefit in median PFS than the
latter (6.0 vs. 5.0 months, P = 0.2039) (Additional file 3:
Figure S1). According to CTC HER2 status, 58 patients
with detectable CTCs were divided into HER2-positive
and -negative groups, and Kaplan-Meier survival curves
to determine the PFS for the 2 groups are shown in Fig. 2.
Though the 58 patients were all histologically HER2-
positive and received anti-HER2 therapy, statistical ana-
lysis demonstrated that the median PFS of CTC HER2-
positive patients was significantly longer than that of CTC
HER2-negative patients (8.5 vs. 3.5 months, P < 0.001). To
eliminate the potential influence of ER and/or PR status
(see univariate Cox regression analysis), the 58 patients
were further divided into hormone receptor-positive and-
negative subgroups, among which Kaplan-Meier plots of
PFS were also created according to CTC HER status. As
Additional file 4: Figure S2A and S2B were shown, com-
pared to CTC HER2-negative patients, anti-HER2 therapy
significantly improved the median PFS of CTC HER2-
positive patients, independent of whether they were
hormone receptor-positive (5.5 vs. 3.0 months, P = 0.036)
or -negative (8.8 vs. 5.0 months, P = 0.016). This finding
was consistent with the results observed in all patients.
Further, the 58 patients with detectable CTC were
divided into 2 subgroups according to the time interval
between their tissue and CTC HER2 testing (> 1 year
and < 1 year). For each subgroup, Kaplan-Meier survival
curves of PFS for CTC HER2-positive and-negative
patients were generated and presented in Fig. 3a and b,
respectively. As the 2 figures show, although the median
PFS of CTC HER2-positive patients was longer than that
of HER2-negative patients, statistical significance was
only found in subgroups with a time interval > 1 year
(6.0 vs. 3.5 months, P = 0.005).
Discussion
Growing evidence has suggested that the HER2 status of
breast cancer patients may change over the course of
therapy and those patients with HER2-overexpressing
primary tumors may not benefit from anti-HER2 therapy
if they lose HER2 expression in their metastatic sites
[26, 27]. In contrast to metastatic lesions, which take time
to emerge and are difficult to biopsy dynamically, the
characterization of CTCs provides the real-time solution
for HER2 status monitoring with the advantages of min-
imal invasiveness and convenient accessibility [14–16].
However, despite its promising utility, the application of
CTC HER2 status testing for directing the use of anti-
HER2 therapy in clinical practice has been greatly ham-
pered due to the variety of CTC detection methods and
Table 1 Characteristic of Patients with CTC detection
Characteristics Total No. patients (%) P
CTC HER2+ CTC HER2-
Overall 58 22 (37.9) 36 (62.1)
Age (years)
Median 48.5 49.0 46.5 0.289
Range 27–68 29–68 27–65
ER and/or PR
Positive 33 8 (24.2) 25 (75.8) 0.014
Negative 25 14 (56.0) 11 (44.0)
No. of Metastasis
1 8 5 (62.5) 3 (37.5) 0.238
≥ 2 50 17 (34.0) 33 (66.0)
Metastatic sites
Visceral 44 16 (36.4) 28 (63.6) 0.663
Non-visceral 14 6 (42.9) 8 (57.1)
DFS
≤ 12 24 12 (50.0) 12 (50.0) 0.111
> 12 34 10 (29.4) 24 (70.6)
Systemic therapy line
1 7 5 (71.4) 2 (28.6) 0.092
≥ 2 51 17 (33.3) 34 (66.7)
Treatment option
Trastuzumab + Chemo 43 19 (44.2) 24 (55.8) 0.096
Lapatinib + Chemo 15 3 (20.0) 12 (80.0)
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Fig. 1 Representative images for the 0, 1+, 2+, and 3+ intensities of HER2 expression on CTCs
Table 2 Cox regression analysis for PFS predicting
Characteristics Univariate analysis Multivariate analysis
HR (95 % CI) P HR (95 % CI) P
Age 0.982 (0.951–1.014) 0.2716 0.978 (0.943–1.015) 0.2371
ER and/or PR: Positive vs. Negative 1.854 (1.015–3.454) 0.0467 1.977 (0.928–4.39) 0.0841
Pathology type: ILC vs. IDC 3.911 (0.215–19.691) 0.1891 3.691 (0.169–31.259) 0.2832
Pathology type: Other vs. IDC 0.936 (0.28–2.336) 0.8995 1.49 (0.395–4.625) 0.5148
CTC Number: ≥ 5 vs. < 5 1.141 (0.631–2.064) 0.6606 1.321 (0.686–2.581) 0.4068
CTC Her2: Positive vs. Negative 0.321 (0.156–0.62) 0.0011 0.383 (0.166–0.831) 0.019
No. of Metastasis: ≥ 2 vs. = 1 0.968 (0.441–2.551) 0.9406 0.746 (0.296–2.155) 0.5566
Metastatic sites: Visceral vs. Non-visceral 0.812 (0.431–1.637) 0.5357 0.591 (0.276–1.356) 0.1907
Systemic therapy line: ≥ 2 vs. = 1 2.309 (0.84–9.543) 0.1619 2.041 (0.626–9.313) 0.2856
Treatment option: L + Che vs. T + Che 0.859 (0.446–1.789) 0.6639 0.911 (0.411–1.863) 0.8063
Abbreviation: IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, L lapatinib, T trastuzumab, Che chemotherapy, HR hazard rate
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the inconsistency in the definition of CTC HER2
positivity.
In this study, we validated definition for CTCs HER-2
positivity that derives from a series of technical consid-
erations and takes into account the work in this field by
other groups [21, 23–25]. We believe this definition
reduces the subjectivity of the molecular testing neces-
sary when proposing the clinical application of the test.
In summary, we used proposed a definition for CTC
HER2 positivity as > 30 % of CTCs overexpressing HER2
(3+) [21]. Unlike other proposed criteria for defining
HER2 positivity in CTCs, our criterion was based on the
Fig. 2 Kaplan-Meier PFS plots of CTC HER2-positive and-negative patients. PFS was calculated from the time of the baseline blood draw.
The coordinates of the dashed lines indicate the median survival time
Fig. 3 Kaplan-Meier PFS plots of CTC HER2-positive and -negative patients in subgroups of time interval (between tissue and CTC HER2 testing) > 1 year
(a) and < 1 year (b). PFS was calculated from the time of the baseline blood draw. The coordinates of the dashed lines indicate median survival time
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standardized CellSearch™ system and takes into account
both the intensity and percentage of CTC HER2-positive
cells, emphasizing a comprehensive analysis of CTCs. In
the first study, although our criterion was verified by the
PFS of patients who received anti-HER2 therapy, the
evidence was not strong enough due to the small sample
size. In the present study, with the inclusion of a larger
cohort of patients we could successfully demonstrate in
univariate and multivariate Cox regression analysis the
predictive value of CTC HER2 status in patients receiving
anti-HER2 therapy.
Notably, the transforming of positive HER2 in tissue to
negative HER2 in CTC was very common. In our present
and previous study [21], the data was 62.1 % (36/58) and
51.8 % (14/27), respectively. In other literatures, though
different CTC HER2 positive criterion was used, similar
results were achieved, and the data of Pestrin et al.,
Riethdorf et al., and Ignatiadis et al. was 41.7 % (5/12)
[23], 45.5 % (5/11) [24] and 50 % (1/2) [25], respectively.
Such high discordant rate re-emphasized the necessity
and urgency of real-time HER2 testing, especially in some
developing countries (e.g., China) where anti-HER2 ther-
apy is still not included in medical insurance and the high
cost of this drug remains a great burden on patients. With
the real-time characterization of CTCs, histologically
HER2-positive but CTC HER2-negative patients may
avoid the overtreatment with anti-HER2 therapy, which
may increase health care costs (e.g., the cost of each cycle
treatment of trastuzumab is approximately 24,000 RMB
or 4000 $ in China) but does not necessarily have an
obvious survival benefit. However, things may be different
in developed countries where anti-HER2 therapy has been
included in medical insurance. People don’t need to worry
about the spending of anti-HER2 therapy in HER2 positive
patients, but pay more attention on whether this therapy
may also have function in some histologically HER2-
negative but CTC HER2-positive patients. The ongoing
DETECT III trial in Germany and the TREAT-CTC trail
in European may provide us more evidence for this
question [28].
Actually, DETECT III trial was only 1 part of the DE-
TECT study program, which also include 3 other trials,
namely, DETECT IVa, DETECT IVb and DETECT V/
CHEVENDO. In each trail, different subtype of patients
was enrolled and treated differentially according to the
phenotypes of their CTC [29]. So far as we known, it’s the
biggest prospective study that concerning about the real
time analysis of CTC, more than half of the projected
about 2000 patients have been enrolled. In addition to the
traditional biomarkers in tissue, molecular characterization
of CTC would be taken as an important indicator in this
study for treatment decision making, which may make the
therapy be more accurate and personalized. With the deve-
lopment of the study, the significance of CTC in modifying
treatment option would be established. Due to this reason,
the publication of its final results has attracted broad atten-
tion and was most eagerly expected.
Interestingly, CTC numbers were found not correlated
with patient’s PFS in present study, not matter with cut-
off of 1 or 5. This result was similar with the report of
Giordano A et al. [30], but inconsistent with our previous
studies [19, 21]. We presume that the reason may due to
receiving or not receiving anti-HER2 therapy. In present
study, only those patients who were going to receive anti-
HER2 therapy were enrolled, similar with the report of
Giordano A et al. However, in our previous studies, some
HER2 positive patients refused the doctor’s recommenda-
tion for anti-HER2 therapy due to financial consideration.
That’s the main difference between the above studies.
Though it still need further verification, this observation
remind us that HER2 analysis on CTC may outweigh the
enumeration of CTC for histological HER2 positive pa-
tients who received anti-HER2 therapy, re-emphasizing
the importance of real-time characteristic of CTC.
In addition, our results showed that the discordance
between tissue and CTC HER2 status may correlate with
the time interval between histological and CTC HER2
testing and is more likely to occur in the subgroups with
an interval of >1 year. For tissue HER2-positive patients,
the loss of HER2 may due to clonal selection under ther-
apy [26]. Hence, it is understandable that this probability
may increase along with the increased time interval
between histological HER2 testing and anti-HER2 ther-
apy. Meanwhile, with regard to median PFS, statistical
significance was only found in the subgroups of patients
with a time interval >1 year, indicating that the longer
the time interval between tissue HER2 testing and anti-
HER2 therapy, the more necessary it is to repeat tissue
biopsy with assessment of the HER-2 status, but more
importantly to evaluate the heterogeneity of disease by a
real-time HER2 status of the patients.
One limitation of our study is that CTC data is based on
one-time sampling and no additional blood draws were
performed. Dynamic analysis should be warranted in the
future, because it is possible that CTC count and CTC
HER2 status may change over the 24-month follow-up
period. In addition, it was reported that histologically
HER2-positive patients may display a lower expression
level of EpCAM [31] (the indispensable biomarker for
CTC enrichment in CellSearch system), which may
explain our finding that no CTCs were detected in 42.6 %
(43/101) of the enrolled patients. Among those with
detectable CTCs, 62.1 % (36/58) of them had a CTC
number ranging from 1 to 10 (see Additional file 2: Table
S2). We recognize that this level of CTC capturing effi-
ciency may inevitably influence the possibility to accurately
evaluate CTC HER2 status. We believe that in the future,
the application of real-time HER2 testing of CTCs in
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clinical practice will expand also using a number of new
and more sensitive and standardized CTC assays.
Conclusions
Our study presents the prognostic value of CTC-HER2
status in patients with HER-2 positive MBC. We validated
the criterion for defining CTC HER2 positivity proposed
in our previous report. The discordance in HER2 status
was confirmed and CTC-HER2 was proved to correlate
with patients’ outcome of anti-HER2 therapy. The study
reinforces the need for evaluation of molecular markers in
advanced disease when possible. Future prospective
studies were needed to expand on this data and focus on
the identification of HER-2 positive patients that may still
benefit from targeted therapies in refractory disease.
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